- Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD products
- Valcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in Europe
- AnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand
Lexaria Bioscience (NASDAQ: LEXX) kicked off the month by announcing an exclusive license to Premier Wellness Science Co. for the use of its patented DehydraTECH(TM) technology in Japan in a variety of CBD products. Announced on June 3, this license would cover oral or non-liquid products and can be used in topical, hair-care, lip-care, and cosmetics segments.
Premier is a wholesale and retail marketer of cosmetics and health foods in Japan. It also provides information and consulting services to entities in the anti-aging, beauty, and health industries. In addition, Premier also offers market research, data collection, and analysis for its clients. The arrangement with Lexaria includes minimum payments of $4.5 million to be paid over the first five years of the deal to maintain exclusivity, with the first payments being made beginning September 1, 2022.
On June 2, 2022, Lexaria announced having signed an agreement granting Valcon Medical A/S rights to use the DehydraTECH platform for medical cannabis applications in Europe. The products subject to this license were classified as non-registered medical products and authorized through country-level programs or EU Commission-registered cannabis products.
Valcon plans to use this platform in bulk powders, solid oral dosage forms, powder-filled capsules, compressed tablets, pills, oral melts, and topical creams and lotions. This non-exclusive license will attract milestone fees from Valcon upon completing batch validation and marketing authorization application approvals. Valcon is a European CMO that is good manufacturing practice (“GMP”) certified. It is licensed in Denmark to manufacture medical cannabis and works with partners to provide contract processing and bulk extract services.
On June 8, 2021, Lexaria announced having granted a pharmaceutical license for using its DehydraTECH platform to AnodGen Bioceuticals. AnodGen, a contract manufacturing organization (“CMO”), manufactures and distributes active pharmaceutical ingredients for the pharmaceutical industry by focusing on plant-based medicine.
With Lexaria’s license, AnodGen will manufacture and distribute cannabidiol (“CBD”) active pharmaceutical ingredient (“API”) powders in Europe, Australia, and New Zealand. The license covers both pharmaceutical and medical product applications for psychoactive cannabinoids and medical applications for non-psychoactive cannabinoids. In addition, it can also be extended to third-party companies to use in their products.
Lexaria is confident that with these newly awarded licenses and ongoing research in hypertension and nicotine, it is preparing for increased global utilization of its technology and for increased cashflows in its journey towards profitability.
In an interview with Unboxing Biotech (https://ibn.fm/EOkaJ) Chris Bunka, Lexaria’s CEO, shared his optimism for the company. In addition, he highlighted the company’s progress and the strides it would make as time progresses. More specifically, he acknowledged the advancement made so far regarding DehydraTECH and potential hypertension treatment, along with the company tapping into the nicotine replacement therapy (“NRT”) market.
Lexaria held its 2022 annual meeting on May 31, 2022. One of the key agendas in the meeting was the appointment of directors and an auditor for the current and future financial years. In the meeting represented by approximately half of all shareholders shares, all the nominated directors and auditor Davidson & Company LLP were approved. This would set the stage for Lexaria’s material partnerships that would define the month of June, as described in a recent Zacks report and interview covering Lexaria (https://ibn.fm/5UolH).
Going forward, Lexaria looks to follow through with its clinical studies, advance its research and forge even more partnerships with other key players in the CBD space. In addition, the company looks to leverage its unique value proposition to grow its revenue and create value for its shareholders.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.